Related and Nonrelated Parties [Axis] Related Party [Member] Class of Stock [Axis] Series A2 Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series A-2 Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Business Combination [Axis] NanoSynex, Ltd. [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Subscription Agreement [Member] Crypto Asset [Axis] Cardano ADA (ADA) [Member] Native BNB (BSC) [Member] Bitcoin (BTC) [Member] Ethereum (ETH) [Member] ChainLink (LINK) [Member] Solana (SOL) [Member] Tron (TRX) [Member] USD Tether (USDT) [Member] Ripple (XRP) [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Faraday Future Intelligent Electric Inc [Member] Location, Statement of Income, Balance [Axis] Short-Term Debt, Type [Axis] Marizyme Notes [Member] Class of Warrant or Right [Axis] Pre Funded Warrants [Member] Series C Warrants [Member] Common Stock Warrants [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Weighted Average [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Measurement Input, Expected Dividend Rate [Member] Debt Instrument [Axis] 2025 Convertible Note [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Award Type [Axis] Upfront Payment [Member] License Agreement [Member] Sponsored Research and License Agreement [Member] Legal Entity [Axis] University of Louisville Research Foundation [Member] License and Sponsored Research Agreements [Member] Phase 1 Clinical Trial [Member] Phase 2 Clinical Trial [Member] Phase 3 Clinical Trial [Member] Product and Service [Axis] Licensed Product Sales [Member] Sponsored Research Agreements And License [Member] Co Development Agreement [Member] Faraday Subscription Agreement [Member] Investor [Member] Legal Firm [Member] Advisor [Member] Common Stock Purchase Agreement [Member] Series A-3 Convertible Preferred Stock [Member] Title and Position [Axis] Yi Hua Chen [Member] Series A-2 and A-3 Convertible Preferred Stock [Member] Plan Name [Axis] 2025 Stock Incentive Plan [Member] Compensatory Warrant Activity [Member] Alpha Capital [Member] Noncompensatory Equity Classified Warrants [Member] Securities Purchase Agreement [Member] Convertible Debt [Member] Placement Agent Warrants [Member] Non Compensatory Warrant Activity [Member] Sale of Stock [Axis] Private Placement [Member] Lead Investor Agreement [Member] Executive Committee [Member] Chief Executive Officer [Member] President [Member] Master Service Agreement [Member] Faraday Future Global Partners [Member] Segment Reporting Expense Information [Member] Common Class A [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement [Table] Statement [Line Items] ASSETS Current assets Cash and cash equivalents Digital Assets Prepaid investments – related party Prepaid expenses and other current assets Short-term notes receivable, net of allowance for credit losses of $4.7 million at March 31, 2026 and $4.6 million at December 31, 2025 Total current assets Non-current assets Intangible assets Other assets - related party Total non-current assets Total Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Related Party Payable Accrued expenses and other current liabilities Warrant liabilities Convertible debt Total current liabilities Commitments and Contingencies (Note 12) Stockholders’ Equity Preferred stock, value Common stock, $0.001 par value; 225,000,000 shares authorized; 20,234,993 and 5,160,383 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Equity Total Liabilities & Stockholders’ Equity Short-term note receivables net of allowance for credit losses Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] EXPENSES General and administrative Sales and Marketing Research and development Credit loss expense - short-term note receivable Total expenses LOSS FROM OPERATIONS OTHER EXPENSE (INCOME), NET Gain on change in fair value of warrant liabilities Gain on change in fair value of convertible debt Impairment of intangible assets Interest expense Interest income Net loss on digital assets Total other expense (income), net LOSS BEFORE PROVISION FOR INCOME TAXES PROVISION FOR INCOME TAXES NET LOSS Total net loss per common share, basic Total net loss per common share, diluted Weighted-average number of shares outstanding, basic Weighted-average number of shares outstanding, diluted Balance Balance, shares Issuance of common stock for the conversion of Series B preferred shares Issuance of common stock for the conversion of Series B preferred shares, shares Net loss Issuance of common stock for the conversion of Series A-2 preferred shares Issuance of common stock for the conversion of Series A-2 preferred shares, shares Stock-based compensation Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile loss from operations to net cash used in operating activities: Stock-based compensation Change in fair value of warrant liabilities Provision for credit losses of short-term note receivable Accrued interest on short-term note receivable Interest expense Payments made with digital assets Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued expenses and other current liabilities Related party payables Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Issuance of short-term note receivable Prepayment of investments to related party Purchase of digital assets Sales of digital assets Purchase of intangible assets Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of convertible debt Proceeds from issuance of promissory notes Net cash provided by (used in) financing activities Net change in cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents- end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest Taxes NONCASH FINANCING AND INVESTING ACTIVITIES: Issuance of common stock for the conversion of Series B preferred shares Issuance of common stock for the conversion of Series A-2 preferred shares Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES LIQUIDITY AND GOING CONCERN Intangible Asset, Goodwill and Other [Abstract] DIGITAL ASSETS Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID INVESTMENT, PREPAID EXPENSES AND OTHER CURRENT ASSETS Receivables [Abstract] SHORT-TERM NOTES RECEIVABLE Payables and Accruals [Abstract] ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Warrant Liabilities WARRANT LIABILITIES Debt Disclosure [Abstract] CONVERTIBLE DEBT PROMISSORY NOTES Earnings Per Share [Abstract] LOSS PER SHARE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Research And License Agreements RESEARCH AND LICENSE AGREEMENTS Equity [Abstract] STOCKHOLDERS’ EQUITY Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Segment Reporting [Abstract] SEGMENT INFORMATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Corporate History Basis of Presentation Principles of Consolidation Accounting Estimates Related Parties and Related Party Transactions Cash and Cash Equivalents Digital Assets Prepaid Investments Software Capitalization Derivative Financial Instruments and Warrant Liabilities Fair Value Measurements Fair Value of Financial Instruments Sales and Marketing Stock-Based Compensation Income Taxes Recently Adopted Accounting Standards Recently Issued Accounting Standards Not Yet Adopted SCHEDULE OF CRYPTO ASSET HOLDINGS SCHEDULE OF DIGITAL ASSET ACTIVITY SCHEDULE OF FAIR VALUE MEASUREMENTS SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF SHORT-TERM NOTE RECEIVABLE SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF FAIR VALUE OF HIERARCHY FOR WARRANT LIABILITIES SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] SCHEDULE OF RESERVED SHARES SCHEDULE OF OUTSTANDING PREFERRED STOCK SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY SCHEDULE OF SEGMENT INFORMATION Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Voting interests acquired Proceeds from issuance of common stock Net proceeds Issuance costs Net proceeds from the Offerings Sales and marketing expenses Cash Retained Earnings (Accumulated Deficit) Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Proceeds from other equity Crypto Asset, Holding [Table] Crypto Asset, Holding [Line Items] Crypto asset number of units Crypto asset cost basis Crypto asset fair value Balance at December 31, 2025 Additions Dispositions Gains Losses Payments made Balance at March 31, 2026 Unrealized gains of digital assets Realized loss of digital assets Unrealized loss of digital assets Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Assets Money Market funds Total Assets Liabilities Convertible Debt Warrant Liabilities Total Liabilities PrepaidExpenseAndOtherAssetsCurrentTable [Table] Defined Benefit Plan Disclosure [Line Items] Prepaid investments Prepayment of investments Prepaid consulting Prepaid insurance Prepaid legal Other current assets Prepaid expenses and other current assets  Short-term note receivable - Marizyme Less allowance for credit losses Short-term notes receivable  Short-Term Debt [Table] Principal amount Accrued interest Accrued interest on short-term note receivable Interest rate Expected credit losses License fees Credit card Professional fees Employee benefits Accrued expenses and other current liabilities  Class of Warrant or Right [Table] Warrants to purchase common shares Warrants exercise price Fair value of warrant liabilities Warrant liabilities Number of Shares, Warrants Outstanding Beginning Weighted Average Exercise Price Per Share Warrants Outstanding Beginning Range of Exercise Price, Beginning Weighted-Average Remaining Life (Years) Outstanding Number of Shares, Warrants Granted Weighted Average Exercise Price Per Share Warrants Granted Range of Exercise Price, Granted Number of Shares, Warrants Exercised Weighted Average Exercise Price Per Share Warrants Exercised Range of Exercise Price, Exercised Number of Shares, Reclassified from equity Weighted Average Exercise Price Per Share Warrants Outstanding Beginning Range of Exercise Price, Reclassified from equity Number of Shares, Reclassified to equity Weighted Average Exercise Price Per Share Warrants Outstanding Beginning Range of Exercise Price, Reclassified to equity Number of Shares, Warrants Expired Weighted Average Exercise Price Per Share Warrants Expired Range of Expired Price Number of Shares, Warrants Outstanding Ending Weighted Average Exercise Price Per Share Warrants Outstanding Ending Range of Exercise Price, Ending Number of Shares, Warrants Exercisable Weighted Average Exercise Price Per Share Warrants Exercisable Range of Exercise Price, Exercisable Weighted-Average Remaining Life (Years) Exercisable Class of Warrant or Right [Line Items] Warrants with no expiration Defined Benefit Plan [Table] Balance Granted Exercised Loss on change in fair value of warrant liabilities Balance Business Combination [Table] Business Combination [Line Items] Warrants outstanding, measurement input Term of warrants (in years) Short-Term Debt [Line Items] Original issue discount Carrying amount Other expense Share price Fair value of convertible securities Proceeds from issuance of convertible note Issuance cost Gain loss on extinguishment of debt Change in fair value of convertible note Notes payable Proceeds from short term debt Repayments of outstanding promissory notes Interest expense Net loss used for basic earnings per share Basic weighted-average common shares outstanding Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants Diluted weighted-average common shares outstanding Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total common stock equivalents Research and Development, Contract to Perform for Others [Table] Reimbursement of patent License cost Reimbursement of research expenses License and sponsored research agreement terms Milestone payment Cumulative sales Cumulative sales Revenue Upfront license fee Research and development expenses Proceeds from convertible debt Patent costs Marketing approval expenses Regulatory marketing approval, expenses Shortfall payments Marizyme agreement terms Exclusivity Fee Debt funded to Marizyme Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total Preferred stock, conversion price Preferred stock, common stock equivalent Range of exercise price - beginning Weighted Average Remaining Life (Years) - outstanding Number of Shares, Warrants Exercised Weighted average exercise price per share warrants exercised Number of Shares, Warrants Expired Weighted average exercise price per share warrants expired Number of Shares, Warrants Forfeited Weighted average exercise price per share warrants forfeited Range of exercise price - ending Number of Shares, Warrants Exercisable Weighted Average Exercise Price Per Share Exercisable Range of exercise price, exercisable Weighted Average Remaining Life (Years) Exercisable Number of shares, warrants non-exercisable Weighted Average Exercise Price Per Share Non-Exercisable Range of Exercise Price, Non-Exercisable Weighted average remaining life (Years) exercisable Number of shares, warrants outstanding granted Weighted average exercise price, warrants granted Range of exercise price warrant, granted Weighted average exercise price, warrants exercised Range of Exercise Price, Exercised Weighted average exercise price, warrants expired Range of Exercise Price, Expired Number of Shares, Warrants Forfeited Weighted average exercise price, warrants forfeited Range of Exercise Price, Forfeited Weighted average exercise price, exercisable Weighted average remaining life (Years) exercisable Number of Shares, Warrants Exercisable Weighted average exercise price, exercisable Range of exercise price, Non-exercisable Common stock reserved for future issuance Number of shares issued and sold Common stock purchase price per share Value of shares sold Warrant to purchase shares of common stock Exercise price Warrants outstanding Value of shares available for sale Preferred stock, shares designated Share price Gross proceeds from issuance of shares Deemed dividend Offering expenses Net proceeds Shares issued upon debt exchange Debt amount exchanged Common shares issuable upon conversion Preferred stock converted Conversion price, per share Floor price, per share Share price, per share Options outstanding Number of warrants issued Warrant exercised Range of Exercise Price, Expired Unrecognized compensation cost Deemed dividend Warrants exercised Weighted average exercise price per share warrants reclassified to liabilities Fair value of warrants reclassified to liabilities from equity Related Party Transaction [Table] Related Party Transaction [Line Items] Investments Proceeds from investor Transition services charged Transition services charged Consulting services fee Related party payable Warrant to purchase shares Weighted average exercise price Cumulative proceeds from issuance of warrants Warrant to purchase shares of common stock Warrants shares Fair value of warrants on grant date Warrant liabilities Total other expense (income), net  NET LOSS Number of reportable segment Subsequent Event [Table] Subsequent Event [Line Items] Unsecured loan Common stock shares reserved for future issuance Common stock par value 2025 Convertible Note [Member] Change in fair value of convertible note. Warrant liabilities current. Credit loss expense short term note receivable. Research And License Agreements [Text Block] Reimbursement of patent. License Agreement [Member] Upfront Payment [Member] Loss gain on change in fair value of warrant liabilities. Gain on change in fair value of convertible debt. Series A-2 Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Stock Issued During Period Value Issuance Of Series A-2 Preferred Shares Conversion. License costs. Reimbursement of research expenses. Sponsored Research and License Agreement [Member] University of Louisville Research Foundation [Member] Agreement term payment, description. Milestone payment. License and Sponsored Research Agreements [Member] Phase 3 Clinical Trial [Member] Phase 1 Clinical Trial [Member] Phase 2 Clinical Trial [Member] Cumulative sales one. Licensed Product Sales [Member] Cumulative sales. Upfront license fee. Sponsored Research Agreements And License [Member] Issuance of common stock for the conversion of Series B preferred shares. Stock issued during period shares issuance of Series A-2 Preferred Shares Conversion. Patent costs. Issuance of common stock for the conversion of Series B preferred shares, shares. Regulatory marketing approval, expenses. Regulatory marketing approval expenses one. Shortfall payments. Co Development Agreement [Member] Faraday Subscription Agreement [Member] Legal Firm [Member] Advisor [Member] Common Stock Purchase Agreement [Member] Series A-3 Convertible Preferred Stock [Member] Deemed dividend arising from warrant modification. Changes in fair value of deemed dividend. Accrued interest on short-term note receivable. Payments made with digital assets. Yi Hua Chen [Member] Series A-2 and A-3 Convertible Preferred Stock [Member] Issuance of common stock for the conversion of Series A-2 preferred shares. NanoSynex, Ltd. [Member] Subscription Agreement [Member] Related Parties and Related Party Transactions [Policy Text Block] Disclosure of accounting policy for platform operators crypto asset. Software Capitalization [Policy Text Block] Derivative Financial Instruments and Warrant Liabilities [Policy Text Block] Disclosure of accounting policy pertaining to accounting standards updates not yet adopted Cardano ADA (ADA) [Member] Native BNB (BSC) [Member] Bitcoin (BTC) [Member] Ethereum (ETH) [Member] ChainLink (LINK) [Member] Solana (SOL) [Member] Tron (TRX) [Member] USD Tether (USDT) [Member] Ripple (XRP) [Member] Debt instrument floor price. 2025 Stock Incentive Plan [Member] Summary of Warrant Activity [Table Text Block] Compensatory Warrant Activity [Member] The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan. Number of shares, warrants non-exercisable (non-vested). Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Weighted average exercise price per share warrants exercised. Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price. Weighted average exercise price per share warrants forfeited. Weighted average exercise price per share exercisable (vested). Weighted average exercise price per share non-exercisable (non-vested). Range Of Exercise Price Outstanding. Range of exercise price, exercisable (vested). Range of exercise price, non-exercisable (non-vested). Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one. Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Range of exercise price expired. Alpha Capital [Member] Noncompensatory Equity Classified Warrants [Member] Securities Purchase Agreement [Member] Pre Funded Warrants [Member] Share based compensation arrangement by share based payment award non option equity instruments prefunded investor warrants exercised. Share based compensation arrangement by share based payment award non option equity instruments reclassified to liabilities in period weighted average exercise price. Money market funds fair value disclosure. Fair value of warrants reclassified to liabilities from equity. Placement Agent Warrants [Member] Non Compensatory Warrant Activity [Member] Share based compensation arrangement by share based payment award non option equity instruments non exercisable number. Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization. Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price. Range of exercise price exercisable granted. Range of exercise price exercisable excercised. Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price. Nonoption equity instrument forfeited in range of exercise price. Warrant liabilities fair value disclosures. Prepaid consulting. Prepaid legal. Prepaid investments. Proceeds from investor. Lead Investor Agreement [Member] Master Service Agreement [Member] Faraday Future Global Partners [Member] Marizyme Notes [Member] Accrued license fees. Accrued credit card. Warrant Liabilities [Text Block] Fair value of warrant liabilities on date of granted. Fair value of warrant liabilities current. Gain (loss) on change in fair value of warrant liabilities. Series C Warrants [Member] Common Stock Warrants [Member] Share based compensation arrangement by share based payment award non option equity instruments reclassified from equity. Share based compensation arrangement by share based payment award non option equity instruments reclassified to equity. Segment Reporting Expense Information [Member] Share based compensation arrangement by share based payment award non option equity instruments grants in period weighted average reclassified equity price. Share based compensation arrangement by share based payment award non option equity instruments reclassified to equity price. Range of exercise price. Range of exercise price granted. Range of exercise price excerised. Range of exercise price reclassified from equity. Range of exercise price reclassified to equity. Range of expired price. Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Fair value measurement with unobservable inputs reconciliation recurring basis liability exercised. Series A2 Preferred Stock [Member] Prepaid investments related party. Prepaid Investments [Policy Text Block] Faraday Future Intelligent Electric Inc [Member] Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) LossGainOnChangeInFairValueOfWarrantLiabilities GainOnChangeInFairValueOfConvertibleDebt Investment Income, Interest Crypto Asset, Realized Gain (Loss), Operating Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Interest Expense, Operating and Nonoperating Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments for (Proceeds from) Loans Receivable Payment for Acquisition, Crypto Asset Payments to Acquire Intangible Assets Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Repayments of Convertible Debt Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Stock Issued IssuanceOfCommonStockForConversionOfPreferredShares Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name PlatformOperatorsCryptoAssetPolicyTextBlock Selling, General and Administrative Expenses, Policy [Policy Text Block] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Crypto Asset, Sale Crypto Asset, Realized and Unrealized Loss, Operating Crypto Asset, Payment for Service WarrantLiabilitiesFairValueDisclosures Accrued Liabilities, Current Warrants and Rights Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice RangeOfExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Interest Expense, Debt CumulativeSales Range of exercise price outstanding RangeOfExercisePriceExercisableExcercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber Shares Issued, Price Per Share Proceeds from Issuance or Sale of Equity RangeOfExercisePriceExpired DeemedDividendArisingFromWarrantModification FairValueOfWarrantLiabilitiesCurrent